With European approval secured, BioMarin puts roughly $1.5M price tag on hemophilia gene therapy
Bio Pharma Dive
AUGUST 25, 2022
On a conference call, BioMarin executives revealed the anticipated price for Roctavian and the company's initial launch plans, which include pay-for-performance deals customized to different markets.
Let's personalize your content